What Is USP <1207>?

USP <1207> is a United States Pharmacopeia chapter dedicated to Container Closure Integrity Testing for sterile pharmaceutical products. It establishes a science-based framework for evaluating whether packaging systems maintain sterility throughout shelf life and distribution.

The chapter introduces the distinction between deterministic and probabilistic testing methods and emphasizes the regulatory preference for deterministic technologies. Unlike traditional qualitative methods, deterministic approaches provide measurable and reproducible results. USP <1207> promotes the use of objective measurement systems capable of detecting defects that could compromise sterility or stability.

A central concept within USP <1207> is the Maximum Allowable Leakage Limit, often referred to as MALL. This represents the largest leak size that does not pose a risk to product sterility or quality. The selected test method must reliably detect leaks at or below this threshold. Sensitivity alone is not sufficient. The method must demonstrate relevance to real product risk.

USP <1207> also addresses method development, validation expectations, defect challenge studies, and lifecycle application of integrity testing. It encourages manufacturers to justify their method selection through scientific rationale rather than historical precedent.

Deterministic technologies such as Vacuum Decay and High Voltage Leak Detection align with USP <1207> principles because they provide quantitative data and reduced operator dependency. By adopting USP <1207> guidance, manufacturers strengthen regulatory defensibility and ensure that integrity testing reflects measurable risk rather than subjective evaluation.